ID

33157

Description

Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01449773

Lien

https://clinicaltrials.gov/show/NCT01449773

Mots-clés

Versions (1)
  1. 29/11/2018 29/11/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

29 novembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT01449773

Anglais

Eligibility Type 2 Diabetes NCT01449773

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age between 18 and 55 years,
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
plasma tg levels above the 50th percentile for age,
Description

Plasma triglyceride measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0583329
non-smoker,
Description

Non-smoker

Type de données

boolean

Alias
UMLS CUI [1]
C0337672
bmi between 25.0 and 40.0 kg/m2,
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
stable body weight for at least 6 months prior to the study baseline,
Description

Stable body weight

Type de données

boolean

Alias
UMLS CUI [1]
C0517386
hba1c between 6.5 and 8.5%,
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
baseline fasting plasma glucose < 15.0 mmol/l
Description

Plasma fasting glucose measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0583513
patients with de novo type 2 diabetes not taking oral hypoglycemic agents -- - or patients having received stable doses of metformin for at least 3 months before randomization.
Description

Non-Insulin-Dependent Diabetes Mellitus de novo | Oral hypoglycemic Absent | Metformin Dose Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C1515568
UMLS CUI [2,1]
C0359086
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0025598
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
extreme dyslipidemias such as familial hypercholesterolemia,
Description

Dyslipidemias Extreme | Hypercholesterolemia, Familial

Type de données

boolean

Alias
UMLS CUI [1,1]
C0242339
UMLS CUI [1,2]
C0205403
UMLS CUI [2]
C0020445
patients with secondary form of diabetes or acute metabolic diabetic complications,
Description

Secondary diabetes mellitus | Complications of Diabetes Mellitus Metabolic

Type de données

boolean

Alias
UMLS CUI [1]
C0271640
UMLS CUI [2,1]
C0342257
UMLS CUI [2,2]
C0311400
patients having received or being treated with insulin or a thiazolidinedione within the past 6 months,
Description

Insulin | Thiazolidinediones

Type de données

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2]
C1257987
subjects having cvd (chd, cerebrovascular disease or peripheral arterial disease)
Description

Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0010068
UMLS CUI [3]
C0007820
UMLS CUI [4]
C1704436
subjects taking medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents,
Description

Pharmaceutical Preparations Affecting Lipoprotein metabolism | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C1158917
UMLS CUI [2]
C0038317
UMLS CUI [3]
C0304516
UMLS CUI [4]
C0012802
UMLS CUI [5]
C0086440
significant alcohol intake
Description

Alcohol consumption Significant

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001948
UMLS CUI [1,2]
C0750502
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT01449773

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age between 18 and 55 years,
boolean
C0001779 (UMLS CUI [1])
Plasma triglyceride measurement
Item
plasma tg levels above the 50th percentile for age,
boolean
C0583329 (UMLS CUI [1])
Non-smoker
Item
non-smoker,
boolean
C0337672 (UMLS CUI [1])
Body mass index
Item
bmi between 25.0 and 40.0 kg/m2,
boolean
C1305855 (UMLS CUI [1])
Stable body weight
Item
stable body weight for at least 6 months prior to the study baseline,
boolean
C0517386 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c between 6.5 and 8.5%,
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
baseline fasting plasma glucose < 15.0 mmol/l
boolean
C0583513 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus de novo | Oral hypoglycemic Absent | Metformin Dose Stable
Item
patients with de novo type 2 diabetes not taking oral hypoglycemic agents -- - or patients having received stable doses of metformin for at least 3 months before randomization.
boolean
C0011860 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0025598 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Dyslipidemias Extreme | Hypercholesterolemia, Familial
Item
extreme dyslipidemias such as familial hypercholesterolemia,
boolean
C0242339 (UMLS CUI [1,1])
C0205403 (UMLS CUI [1,2])
C0020445 (UMLS CUI [2])
Secondary diabetes mellitus | Complications of Diabetes Mellitus Metabolic
Item
patients with secondary form of diabetes or acute metabolic diabetic complications,
boolean
C0271640 (UMLS CUI [1])
C0342257 (UMLS CUI [2,1])
C0311400 (UMLS CUI [2,2])
Insulin | Thiazolidinediones
Item
patients having received or being treated with insulin or a thiazolidinedione within the past 6 months,
boolean
C0021641 (UMLS CUI [1])
C1257987 (UMLS CUI [2])
Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease
Item
subjects having cvd (chd, cerebrovascular disease or peripheral arterial disease)
boolean
C0007222 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C1704436 (UMLS CUI [4])
Pharmaceutical Preparations Affecting Lipoprotein metabolism | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents
Item
subjects taking medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents,
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1158917 (UMLS CUI [1,3])
C0038317 (UMLS CUI [2])
C0304516 (UMLS CUI [3])
C0012802 (UMLS CUI [4])
C0086440 (UMLS CUI [5])
Alcohol consumption Significant
Item
significant alcohol intake
boolean
C0001948 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial